Compile Data Set for Download or QSAR
Report error Found 35 Enz. Inhib. hit(s) with all data for entry = 3223
TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350343(US9801872, Example 27 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350340((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-chloro...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350339((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)-8-fluo...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350338((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-8-fluoro...)
Affinity DataIC50: 1.26nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350350(US9801872, Example 34 | (S)-5-(1-((1-(2-chloroacet...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350344(US9801872, Example 28 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350342(US9801872, Example 26 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350341(US9801872, Example 25 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350345(US9801872, Example 29 | (S)-3-(1-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350336(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350333((S)-3-(8-((1-acryloylpyrrolidin-3-yl)amino)-1,7-na...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350346(US9801872, Example 30 | (S)-3-(6-((1-acryloylpyrro...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350324((S)-3-(1-((1-acryloylpyrrolidin-3-yl)amino)isoquin...)
Affinity DataIC50: 2.51nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350332((S)-3-(8-((1-acryloylpyrrolidin-3-yl)oxy)-1,7-naph...)
Affinity DataIC50: 3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350327((S)-3-(1-((1-acryloylpyrrolidin-3-yl)(methyl)amino...)
Affinity DataIC50: 3.16nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350348(US9801872, Example 32 | (S)-3-(6-((1-acryloylpyrro...)
Affinity DataIC50: 5.01nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350330((S,E)-5-(1-((1-(4-(dimethylamino)but-2-enoyl)pyrro...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350334((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)-7-fluoro...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350335(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350349(US9801872, Example 33 | (S)-5-(1-((1-(2-chloroacet...)
Affinity DataIC50: 6.31nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350320(N-(1-(3-(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)i...)
Affinity DataIC50: 7.94nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350329((S)-3-(1-(((1-acryloylpyrrolidin-3-yl)oxy)methyl)i...)
Affinity DataIC50: 10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350323((S)-3-(1-((1-acryloylpyrrolidin-2-yl)methoxy)isoqu...)
Affinity DataIC50: 10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350322((S)-3-(1-(((1-acryloylpyrrolidin-2-yl)methyl)amino...)
Affinity DataIC50: 10nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350325((R)-3-(1-((1-acryloylpyrrolidin-2-yl)methoxy)isoqu...)
Affinity DataIC50: 12.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350331((S,E)-3-(1-((1-(but-2-enoyl)pyrrolidin-3-yl)amino)...)
Affinity DataIC50: 25.1nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350351(US9801872, Example 35 | (S)-5-(1-((1-acryloylpiper...)
Affinity DataIC50: 31.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350326((S)-3-(1-((1-methacryloylpyrrolidin-3-yl)amino)iso...)
Affinity DataIC50: 31.6nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350347(US9801872, Example 31 | (S)-3-(6-((1-acryloylpyrro...)
Affinity DataIC50: 63.1nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350318((R)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 79.4nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350335(3-(1-(((3R,4S)-1-acryloyl-4-methylpyrrolidin-3-yl)...)
Affinity DataIC50: 126nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350328((S)-3-(1-((1-methacryloylpyrrolidin-3-yl)oxy)isoqu...)
Affinity DataIC50: 126nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350317((R)-3-(1-((1-methacryloylpyrrolidin-3-yl)oxy)isoqu...)
Affinity DataIC50: 200nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350319((R,E)-3-(1-((1-(but-2-enoyl)pyrrolidin-3-yl)oxy)is...)
Affinity DataIC50: 316nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent